Atebrioz (zilurgisertib fumarate)

Where it stands

Atebrioz (zilurgisertib fumarate), from Mirum, was approved by the US FDA on 2026-09-25 under NDA221198. The record describes it as a new medicine in tablet form. It is the only milestone in the records.

The records leave the indication and therapeutic area blank. This analysis therefore cannot say which patients the product is approved to treat, the dose, or the labeled conditions of use. Those details need to come from the FDA approval letter and the prescribing information.

The records contain no CHMP opinion or EU approval date. On this evidence, the product's status is US-only.

Regulatory pathway and designations

The application was a New Drug Application (NDA221198). The FDA lists the product as a new molecular entity (NME), meaning the active moiety had not previously been approved in the US. NMEs generally go through the full review process rather than an abbreviated route.

The product also had Priority review designation. In general, this designation shortens the FDA's target review clock for drugs that may offer a significant improvement in the treatment, diagnosis or prevention of a serious condition. For an NME, the target is six months from the 60-day filing date. The records do not give the submission date, filing date or goal date, so we cannot say how the review timeline played out.

The records do not show whether other expedited programs applied, such as Breakthrough Therapy, Fast Track, Accelerated Approval or Orphan Drug designation. None should be assumed.

Safety and pharmacovigilance

The records contain no safety information, such as warnings, boxed warnings, risk management requirements or post-marketing commitments, so none can be assessed here.

What to watch

The first step is to obtain the FDA approval package and the final labeling. This will confirm the indication, the population, the dosing and any safety language. It will also show whether the approval carries post-marketing requirements or commitments, including any confirmatory studies.

Next, watch for company communications on US launch timing and on any plans for other regions. The records show no CHMP opinion or EU filing status, so any EU pathway is unconfirmed.

Finally, watch the early post-approval period for the FDA's published review documents and for safety signals reported through routine pharmacovigilance. The records give no information on any of these yet.